Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 3/2016

01-06-2016 | Case Report

A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity

Authors: Eric Nulens, Jens Van Praet, Dominik Selleslag, Thomas Van Landschoot, Dieter Dekeyzer, Patrick Descheemaecker, Marijke Reynders

Published in: Infection | Issue 3/2016

Login to get access

Abstract

Non-urogenital Mycoplasma hominis infections are rare, but may cause life-threatening complications. We describe a case of disseminated M. hominis infection with extensive abscess formation in an immunocompromised patient with iatrogenic hypogammaglobulinemia under rituximab treatment.
Literature
1.
CLSI. Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; Approved Guideline. CLSI document MM18-A. Wayne: Clinical and Laboratory Standards Institute. 2008.
2.
Pailhories H, Rabier V, Eveillard M, Mahaza C, Joly-Guillou M-L, Chennebault J-M, Kempf M, Lemarie C. A case report of Mycoplasma hominis brain abscess identified by MALDI-TOF mass spectrometry. Int J Infect Dis. 2014;29:166–8.CrossRefPubMed
3.
Fenollar F, Gauduchon V, Casalta J-P, Lepidi H, Vandenesch F, Raoult D. Mycoplasma endocarditis: two case reports and a review. Clin Infect Dis. 2004;38:e21–4.CrossRefPubMed
4.
Miana AN, Farney AC, Mendleya SR. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. Am J Transplant. 2005;5:183–8.CrossRef
5.
MacKenzie CR, Nischik N, Kram R, Krauspe R, Jäger M, Henrich B. Fatal outcome of a disseminated dual infection with drug-resistant Mycoplasma hominis and Ureaplasma parvum originating from a septic arthritis in an immunocompromised patient. Int J Infect Dis. 2010;14(Suppl 3):e307–9.CrossRefPubMed
6.
Wylam ME, Kennedy CC, Hernandez NM, Peters SG, Maleszewski JJ, Cassivi SD, Scott JP. Fatal hyperammonaemia caused by Mycoplasma hominis. Lancet. 2013;382:1956.CrossRefPubMed
7.
Meyer RD, Clough W. Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression. Clin Infect Dis. 1993;17:S243–9.CrossRefPubMed
8.
Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol. 2010;91:501–8.CrossRefPubMed
9.
Gdoura R, Kchaou W, Chiraz Chaari C, Abir Znazen A, Leila Keskes L, Tarek Rebai T, Hammami A. Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis and Mycoplasma genitalium infections and semen quality of infertile men. BMC Infect Dis. 2007;7:129.CrossRefPubMedPubMedCentral
10.
Waites KB, Crabb DM, Duffy LB. Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human Mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother. 2008;10:3776–8.CrossRef
11.
Krausse R, Schubert S. In-Vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. Isolated in Germany over 20 years. Clin Microbiol Infect. 2010;16:1649–55.CrossRefPubMed
12.
Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001;45:2604–8.CrossRefPubMedPubMedCentral
13.
Pereyre S, Tardy F, Renaudin H, Cauvin E, del Prá Netto Machado L, Tricot A, Benoit F, Treilles M, Bébéar C. Identification and subtyping of clinically relevant human and ruminant Mycoplasmas by use of matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol. 2013;51:3314–23.CrossRefPubMedPubMedCentral
Metadata
Title
A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity
Authors
Eric Nulens
Jens Van Praet
Dominik Selleslag
Thomas Van Landschoot
Dieter Dekeyzer
Patrick Descheemaecker
Marijke Reynders
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 3/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0859-6

Other articles of this Issue 3/2016

Infection 3/2016 Go to the issue

Original Paper

Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children

Case Report

Clindamycin-induced hypersensitivity reaction

Review

Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci

Case Report

Necrotizing fasciitis due to Serratia marcescens: case report and review of the literature

Review

The “Choosing Wisely”: initiative in infectious diseases

Images in Infection

Refractory tenosynovitis with ‘rice bodies’ in the hand due to Mycobacterium intracellulare
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits